$ARBE good question but no any real answer.
today i watched a video: why adas cars not ready, where are problem? it was a 5 year old video. worst than that professor at vid. is death .
it is highly risky, unready, unavailable tech. arbe just sold oem selection hopium and now they give no hope about that.
we ve some deals but u know biotechs, they always burn investors money and i see that some of them go bankcrupcy when their product ready $ADAPY $CLSD
i believe positive things are also deals. As if they are not too small, company achieve to not sunking, float level, our price reevaluate with consider possibible future wins btw 2-4 . Some legal things may force oems but it is not suprise for me as if legal codes completely unlinked with 4d radar.
if tesla want to maintain its establihment logic, i think they should deal with us. Chinese oem may trigger others
$CLSD they are coming out of bankruptcy, more details soon. Shareholders maintain 70% ownership, 20% voting power prior to any further dilution. Waiting to see what was excluded from the sales…
$CLSD We might not get back to the pre reverse split and bk price anytime soon but we still have the SCS ip, the TKI, the NOL's and some royalties...even in spite of the 30% Steele partner stake and possible further future dilution, there is still significant value here. More, much more than 25 cents!
$CLSD well, voted my shares for the the restructuring plan as there appeared to be the best alternative…we’ll know the outcome by 7/1 or shortly after.
$RGNX $CLSD Quick look and it appears that Clearside is going to reorganize, here's AI take:
Key DetailsThe License Remains Intact: Regenxbio has an exclusive worldwide license (exercised in 2019) for the SCS Microinjector specifically for delivering AAV gene therapies (notably RGX-314 / ABBV-RGX-314) in wet AMD, diabetic retinopathy (DR), and related indications. This license includes supply obligations from Clearside. In a Chapter 11 reorganization (as opposed to a full liquidation), existing executory contracts like this license are typically assumed by the reorganized company.
Steel Partners Reorganization:Steel Partners is providing new capital and becoming a major owner of the reorganized Clearside.
The plan focuses on preserving and monetizing the SCS platform and licensing agreements (including Regenxbio’s).
This is far better for partners like Regenxbio than if a random low bidder had won the assets and potentially tried to renegotiate or disrupt supply.
$CLSD Federal corp tax rate is 21%. NOLs are worth $52M (250M NOLs), plus a $12M carried R&D tax credit, so the total value of the shell is $64M. Yet the CLSD team has negotiated a deal with Steele that lacks a guarantee for even a small portion of this money to be paid to CLSD shareholders. Steele can dilute class A shareholders 1000x, and then fold a profitable company into clsd and take the NOLs. You could own a worthless, infinitesimal portion of this new combined company. It will be trading on the pink sheets with no SEC reporting (that is a fact included in the docket). The proposed reverse split is in the docket too.
Trying to get more info. But for now, I'm holding my vote with an intent to vote no unless they come up with a better deal for shareholders where there is an assurance we get paid at least a portion of the NOL value.
I'm not the only large shareholder in this camp. They need yes votes from 2/3 of the votes cast for the proposal to pass. Voting deadline is 6/24.
